Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO
· The abstract describes the dose-escalation part of the ONCOS-102 and durvalumab combination trial in peritoneal malignancies · The abstract has been selected for the Poster Discussion Session Developmental Therapeutics—Immunotherapy to be presented 29 May at the ASCO 2020 virtual meeting Oslo, Norway, 14 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that an abstract relating to the dose escalation part of the ONCOS-102 and durvalumab trial in primary ovarian and